PUBLICATION
Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish
- Authors
- Lelieveld, L.T., Mirzaian, M., Kuo, C.L., Artola, M., Ferraz, M.J., Peter, R.E.A., Akiyama, H., Greimel, P., van den Berg, R.J., Overkleeft, H.S., Boot, R.G., Meijer, A., Aerts, J.M.F.G.
- ID
- ZDB-PUB-190929-10
- Date
- 2019
- Source
- Journal of Lipid Research 60(11): 1851-1867 (Journal)
- Registered Authors
- Meijer, Annemarie H.
- Keywords
- Cerebrosides, Gaucher's disease, Lipidomics, Mass spectrometry, Sphingolipids, Storage diseases, Zebrafish models, lipid metabolism, lysosphingolipids
- MeSH Terms
-
- Animals
- Cells, Cultured
- Glucosylceramidase/deficiency*
- Glucosylceramidase/metabolism
- Glycosphingolipids/metabolism*
- Models, Biological*
- Zebrafish
- Zebrafish Proteins/deficiency*
- Zebrafish Proteins/metabolism*
- beta-Glucosidase/deficiency
- beta-Glucosidase/metabolism*
- PubMed
- 31562193 Full text @ J. Lipid Res.
Citation
Lelieveld, L.T., Mirzaian, M., Kuo, C.L., Artola, M., Ferraz, M.J., Peter, R.E.A., Akiyama, H., Greimel, P., van den Berg, R.J., Overkleeft, H.S., Boot, R.G., Meijer, A., Aerts, J.M.F.G. (2019) Role of β-glucosidase 2 in aberrant glycosphingolipid metabolism: model of glucocerebrosidase deficiency in zebrafish. Journal of Lipid Research. 60(11):1851-1867.
Abstract
β-glucosidases (GBA1 [glucocerebrosidase], GBA2, and GBA3) are ubiquitous, essential enzymes. Lysosomal GBA1 and cytosol-facing GBA2 degrade glucosylceramide (GlcCer); GBA1 deficiency causes Gaucher disease (GD), a lysosomal storage disorder characterized by lysosomal accumulation of GlcCer, which is partly converted to glucosylsphingosine (GlcSph). GBA1 and GBA2 also may transfer glucose from GlcCer to cholesterol, yielding glucosylated cholesterol (GlcChol). Here, we aimed to clarify the role of zebrafish Gba2 in glycosphingolipid metabolism during Gba1 deficiency in zebrafish (Danio rerio), which are able to survive total Gba1 deficiency. We developed Gba1 and Gba2 zebrafish knockouts (gba1-/- and gba2-/- , respectively) using CRISPR/Cas9, modulated glucosidases genetically and pharmacologically, studied GlcCer metabolism in individual larvae, and explored the feasibility of pharmacologic or genetic interventions. Activity-based probes and quantification of relevant glycolipid metabolites confirmed enzyme deficiency. GlcSph increased in gba1-/- larvae (0.09 pmol/fish) but did not increase more in gba1-/-:gba2-/- larvae. GlcCer was comparable in gba1-/- and wild-type (WT) larvae but increased in gba2-/- and gba1-/-:gba2-/- larvae. Independent of Gba1 status, GlcChol was low in all gba2-/- larvae (0.05 vs. 0.18. pmol/fish in WT). Pharmacologic inactivation of zebrafish Gba1 comparably increased GlcSph. Inhibition of glucosylceramide synthase in Gba1-deficient larvae reduced GlcCer and GlcSph, and concomitant inhibition of glucosylceramide synthase and Gba2 with iminosugars also reduced excessive GlcChol. Finally, overexpression of human GBA1 and injection of recombinant GBA1 both decreased GlcSph. We determined that zebrafish larvae offer an attractive model to study glucosidase actions in glycosphingolipid metabolism in vivo, and we identified distinguishing characteristics of zebrafish Gba2 deficiency.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping